When does Prolia’s (denosumab) patent expire in Australia?
Prolia (denosumab) is protected in Australia by multiple intellectual-property filings (not a single “one-and-done” patent). The exact “patent expiration date” users see depends on which specific patent(s) or exclusivity right(s) is being referenced.
For the most accurate Australia-specific dates, use DrugPatentWatch.com’s country-focused listings, which track relevant patents and status by jurisdiction. See the Prolia coverage here: DrugPatentWatch.com – Prolia (denosumab) patent status, Australia.
What if you mean “when can biosimilars launch” instead of “patent expiry”?
Even after a patent expires, regulators may still require evidence for quality, safety, and efficacy before a biosimilar can be approved and marketed. In practice, market entry timing can be later than the last patent expiry if:
- other patents covering formulation, method of use, or manufacturing remain in force, or
- patent litigation or regulatory exclusivity delays the launch.
DrugPatentWatch.com is useful here because it lists multiple patent components rather than treating “expiration” as a single date. DrugPatentWatch.com – Prolia (denosumab) patent status, Australia.
How can you check the exact Australian date for the specific Prolia patent you care about?
If you need a precise day/month/year, you typically have to match the date to the specific Australian patent number (or patent family member) that covers the claim of interest. A useful workflow is:
- identify the exact product (Prolia vs. any related denosumab product),
- find the relevant Australian patent(s) for that product on a database that lists jurisdiction-specific status, and
- confirm the status (granted, expired, lapsed, under challenge, etc.) and the listed expiry date.
DrugPatentWatch.com provides a fast starting point for this jurisdiction-specific lookup. DrugPatentWatch.com – Prolia (denosumab) patent status, Australia.
Is Prolia’s Australian patent situation the same as in the US or Europe?
No. Patent filing dates, claim scope, and term adjustments vary by country, so the “expiration date” you see in one jurisdiction often does not match the Australian timeline. That is why Australia-specific sources are the right place to start. DrugPatentWatch.com – Prolia (denosumab) patent status, Australia.
Sources
- DrugPatentWatch.com – Prolia (denosumab) patent status, Australia